Structured evidence table for Beta Alanine Exercise Recovery Randomized Trial, generated from 3 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Beta Alanine Exercise Recovery Randomized Trial | Methodological quality was assessed using the Cochrane RoB 2.0 tool, and the certainty of evidence was evaluated via the GRADE framework. | 1 | Liang W (2026) | No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials. |
| Beta Alanine Exercise Recovery Randomized Trial | Conclusion In conclusion, chronic β-alanine supplementation does not provide a clear improvement in total work capacity, maximal anaerobic power, or fatigue resistance during repeated sprinting. | 1 | Liang W (2026) | No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials. |
| Beta Alanine Exercise Recovery Randomized Trial | Objective Chronic beta-alanine supplementation is a prevalent nutritional strategy to augment intracellular buffering capacity via elevated muscle carnosine. | 1 | Liang W (2026) | No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials. |
| Beta Alanine Exercise Recovery Randomized Trial | While its ergogenic efficacy in continuous, high-intensity exercise is established, its impact on repeated sprint ability (RSA)-governed by extremely brief work bouts and phosphocreatine (PCr) kinetics-remains equivocal. | 1 | Liang W (2026) | No ergogeniceffect of β-alanine on repeated sprint ability: a systematic review and multilevel meta-analysis of randomized controlled trials. |
| Beta Alanine Exercise Recovery Randomized Trial | Similarly, no between-roup differences were found for height (= 0.21, = 0.839, = 0.07,rivial effect), BMI (= −0.97, = 0.340, = −0.35, small effec), or body fat percentae (= −1.20, = 0.242, = −0.44, small effec). | 2 | Küçük Furkan Hasan (2026) | Effects of β-alanine supplementation on kickboxing-specific anaerobic performance, neuromuscular power, and strength endurance: A randomized, double-blind, placebo-controlled trial |
| Beta Alanine Exercise Recovery Randomized Trial | Table 3 (26) (26) (26) (26) As shown in, no significant between-group differences were found in baseline physical performance variables (all p > 0.05). | 2 | Küçük Furkan Hasan (2026) | Effects of β-alanine supplementation on kickboxing-specific anaerobic performance, neuromuscular power, and strength endurance: A randomized, double-blind, placebo-controlled trial |
| Beta Alanine Exercise Recovery Randomized Trial | The findings revealed meaningful group × time interaction effects, particularly for KASTtotal, where the β-alanine group improved from 40.36 ± 2.34 s at baseline to 38.85 ± 2.46 s after supplementation, while the control group showed only a minimal change (42.09 ± 3.18 s to 41.50 ± 3.63 s). | 2 | Küçük Furkan Hasan (2026) | Effects of β-alanine supplementation on kickboxing-specific anaerobic performance, neuromuscular power, and strength endurance: A randomized, double-blind, placebo-controlled trial |
| Beta Alanine Exercise Recovery Randomized Trial | 1 2 3 4 1 β-Alanine is a non-essential amino acid that is naturally present in our daily diet and can also be synthesized by our body in the liver through the catabolism of pyrimidine nucleotides. | 2 | Küçük Furkan Hasan (2026) | Effects of β-alanine supplementation on kickboxing-specific anaerobic performance, neuromuscular power, and strength endurance: A randomized, double-blind, placebo-controlled trial |
| Beta Alanine Exercise Recovery Randomized Trial | Consequently, there is a lack of evidence-based medical evidence for the treatment of HFpEF. | 2 | Huang Rufeng (2026) | Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study |
| Beta Alanine Exercise Recovery Randomized Trial | But increasing clinical studies have found that SGLT2i can confer cardiovascular benefits to patients with HFpEF. | 2 | Huang Rufeng (2026) | Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study |
| Beta Alanine Exercise Recovery Randomized Trial | The renowned randomized trials, EMPEROR-Preserved trial and DELIVER trial, have demonstrated that SGLT2i empagliflozin and dapagliflozin can reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with HFrEF and HFpEF [,]. | 2 | Huang Rufeng (2026) | Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study |
| Beta Alanine Exercise Recovery Randomized Trial | 1 2 Heart failure (HF) is a group of complex clinical syndromes characterized by abnormal structural and/or function of the heart due to a variety of causes, leading to impaired ventricular contraction and/or diastolic function. | 2 | Huang Rufeng (2026) | Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study |
Source documents